PTGX insider ownership: who sold, why, and what they still hold

What stands out

Seven insiders sold $31.1M with no disclosed plan: Dinesh Patel ($9.6M), Asif Ali ($6.4M) and Bryan Giraudo ($5.9M), plus 4 more. The filings don't state a reason.Dinesh Patel: largest such sale, Mar 25, 2026 · Asif Ali: largest such sale, Mar 26, 2026 · Bryan Giraudo: largest such sale, May 7, 2026

A share of stake is shown for 0 of the 7 officers and directors who sold. 8 are left out

Left out: Dinesh Patel, Arturo Molina, Asif Ali, Harold Selick, Bryan Giraudo, William Waddill, Lewis Williams and Sarah O'Dowd (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Dinesh Patel

President and CEO, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$53.1M77% planned, 5% to cover taxes 18% no plan disclosed

Asif Ali

Chief Financial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$15.6M53% planned, 6% to cover taxes 41% no plan disclosed

Bryan Giraudo

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$5.9MNo plan disclosed

William Waddill

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.6M64% planned 36% no plan disclosed

Arturo Molina

Chief Medical Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$4.5M23% to cover taxes 77% no plan disclosed

All 7 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

Sep 30, 2026Asif Ali sold 59K shares ($8.3M) under a disclosed trading plan. 59K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Asif Ali Chief Financial Officer	58,629	$141.78	n/a	n/a	Sep 30, 2026	Oct 2, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Common questions

Is the Protagonist Therapeutics, Inc CEO selling stock?

Yes. Dinesh Patel sold 437K shares ($53.1M) in the past 12 months, 77% of it under a trading plan disclosed in the filings.

Why are Protagonist Therapeutics, Inc insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 59% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 5% were to cover taxes and 35% had no disclosed plan. A trading plan schedules sales in advance.

Are any Protagonist Therapeutics, Inc insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold7 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Dinesh Patel President and CEO, Director	$53.1M 437K shares	Not confirmed share of stake is being verified. Why	77% under a disclosed plan, 5% to cover taxes 18% no plan disclosed
Asif Ali Chief Financial Officer	$15.6M 140K shares	Not confirmed share of stake is being verified. Why	53% under a disclosed plan, 6% to cover taxes 41% no plan disclosed
Bryan Giraudo Director	$5.9M 59K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
William Waddill Director	$4.6M 47K shares	Not confirmed share of stake is being verified. Why	64% under a disclosed plan 36% no plan disclosed
Arturo Molina Chief Medical Officer	$4.5M 50K shares	Not confirmed share of stake is being verified. Why	23% to cover taxes 77% no plan disclosed
Harold Selick Director	$2.5M 24K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Lewis Williams Director	$1.5M 18K shares	Not confirmed share of stake is being verified. Why	No plan disclosed

The full ownership picture0 of 8 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Dinesh Patel

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Dinesh Patel are complete.

President and CEO, Director

n/a

−437K

n/a

Vesting, gifts, unvested awards and holding lines for Dinesh Patel

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Dinesh Patel are complete; balances and unit counts will be added when the check is finished.

−58Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
315,250	$23.42	Jan 2, 2034	$37.3M
181,472	$38.98	Jan 2, 2035	$18.7M
120,200	$87.18	Jan 2, 2036	$6.6M

Estimate: options held × ($141.78 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Arturo Molina

Chief Medical Officer

n/a

−50K

n/a

Vesting, gifts, unvested awards and holding lines for Arturo Molina

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Arturo Molina are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
50,971	$8.04	Nov 15, 2032	$6.8M
69,063	$23.42	Jan 2, 2034	$8.2M
47,785	$38.98	Jan 2, 2035	$4.9M
32,000	$87.18	Jan 2, 2036	$1.7M

Estimate: options held × ($141.78 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Asif Ali

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Asif Ali are complete.

Chief Financial Officer

n/a

−140K

n/a

Vesting, gifts, unvested awards and holding lines for Asif Ali

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Asif Ali are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
31,300	$19.19	Apr 18, 2032	$3.8M
13,282	$12.17	Jan 15, 2033	$1.7M
49,562	$23.42	Jan 2, 2034	$5.9M
29,291	$38.98	Jan 2, 2035	$3.0M
32,000	$87.18	Jan 2, 2036	$1.7M
51,150	$19.19	Apr 17, 2032	$6.3M
25,235	$12.17	Jan 15, 2033	$3.3M

Estimate: options held × ($141.78 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Harold Selick

Director

n/a

−24K

n/a

Vesting, gifts, unvested awards and holding lines for Harold Selick

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Harold Selick are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
25,700	$23.42	Jan 2, 2034	$3.0M
6,584	$38.98	Jan 2, 2035	$677K
3,762	$87.18	Jan 2, 2036	$205K

Estimate: options held × ($141.78 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Bryan Giraudo

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Bryan Giraudo are complete.

Director

n/a

−59K

n/a

Vesting, gifts, unvested awards and holding lines for Bryan Giraudo

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Bryan Giraudo are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
25,700	$23.42	Jan 2, 2034	$3.0M
6,584	$38.98	Jan 2, 2035	$677K
3,762	$87.18	Jan 2, 2036	$205K

Estimate: options held × ($141.78 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

William Waddill

Director

n/a

−47K

n/a

Vesting, gifts, unvested awards and holding lines for William Waddill

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for William Waddill are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
25,700	$23.42	Jan 2, 2034	$3.0M
6,584	$38.98	Jan 2, 2035	$677K
3,762	$87.18	Jan 2, 2036	$205K

Estimate: options held × ($141.78 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Lewis Williams

Director

n/a

−18K

n/a

Vesting, gifts, unvested awards and holding lines for Lewis Williams

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Lewis Williams are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
25,700	$23.42	Jan 2, 2034	$3.0M
6,584	$38.98	Jan 2, 2035	$677K
3,762	$87.18	Jan 2, 2036	$205K
6,000	$10.84	Jun 15, 2027	$786K

Estimate: options held × ($141.78 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Sarah O'Dowd

Director

n/a

Vesting, gifts, unvested awards and holding lines for Sarah O'Dowd

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sarah O'Dowd are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
25,700	$23.42	Jan 2, 2034	$3.0M
6,584	$38.98	Jan 2, 2035	$677K
3,762	$87.18	Jan 2, 2036	$205K

Estimate: options held × ($141.78 − strike price), using the most recent insider trade price on Form 4 (Sep 30, 2026), not a market close.

Holdings and share of stake for Protagonist Therapeutics, Inc are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$87.7M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $87.7M across 775,853 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $51.9M · 59%

41%

The lighter segment is sales with no plan disclosed in the filing ($35.8M), including tax-related sales outside a plan.

No plan disclosed · $31.1M

Sales with no 10b5-1 plan and no tax reference in the filing. $9.6M of it is Dinesh Patel. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Dinesh Patel, Mar 25, 2026

Taxes

$4.7M of sales (5.4%) cite tax obligations in their footnotes. Example: Asif Ali, Apr 20, 2026

Charitable gifts · 6K shares

Gifts the filings describe as charitable. Gifts are not sales and are not included in the sale totals.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Dinesh Patel President and CEO, Director	437K	$53.1M	77%	61%	Jan 20, 2026 to Sep 10, 2026
Asif Ali Chief Financial Officer	140K	$15.6M	53%	18%	Jan 20, 2026 to Sep 30, 2026
Bryan Giraudo Director	59K	$5.9M	0%	7%	May 7, 2026 to May 8, 2026
William Waddill Director	47K	$4.6M	64%	5%	Feb 6, 2026 to Jun 23, 2026
Arturo Molina Chief Medical Officer	50K	$4.5M	0%	5%	Nov 17, 2025 to Mar 26, 2026
Harold Selick Director	24K	$2.5M	0%	3%	Mar 26, 2026 to Mar 26, 2026
Lewis Williams Director	18K	$1.5M	0%	2%	Feb 17, 2026 to Feb 17, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$0	$0	$0	$0
Nov 2025	$230K	$0	$230K	$0
Dec 2025	$0	$0	$0	$0
Jan 2026	$14.1M	$0	$4.3M	$9.8M
Feb 2026	$3.2M	$0	$0	$3.2M
Mar 2026	$12.2M	$0	$0	$12.2M
Apr 2026	$185K	$0	$185K	$0
May 2026	$14.3M	$8.4M	$0	$5.9M
Jun 2026	$2.0M	$2.0M	$0	$0
Jul 2026	$0	$0	$0	$0
Aug 2026	$14.9M	$14.9M	$0	$0
Sep 2026	$26.6M	$26.6M	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

More than usual: about 5x the 5-year average. 7 insiders sold; the average is 3 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 13, 2026 Latest 12 months	776K	7	$87.7M
Oct 13, 2025 1 year earlier	433K	5	$21.5M
Oct 13, 2024 2 years earlier	248K	5	$7.3M
Oct 14, 2023 3 years earlier	0	0	$0
Oct 14, 2022 4 years earlier	15K	1	$482K
Oct 14, 2021 5 years earlier	48K	3	$1.5M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty8 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Protagonist Therapeutics, Inc are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology291 filings on record, 36 filed in the 12-month period, and how we read them

All 291 Forms 3, 4 and 5 on record for Protagonist Therapeutics, Inc (SEC CIK 1377121), filed from Aug 10, 2016 to Oct 2, 2026; 36 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (18)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Suneel Gupta	Nov 27, 2024	267,433 shares, last reported balance as of Nov 26, 2024
Daniel Swisher Jr.	Oct 30, 2023	No balance on record
Sarah Noonberg	Jan 18, 2023	No balance on record
David Liu	Nov 17, 2022	167,590 shares, last reported balance as of Nov 16, 2022
Donald Kalkofen	Feb 17, 2022	18,521 shares, last reported balance as of Feb 15, 2022
Samuel Saks	Feb 26, 2021	14,000 shares, last reported balance as of Feb 26, 2021
Chaitan Khosla	Aug 12, 2020	No balance on record
Richard Shames	Mar 4, 2019	32,021 shares, last reported balance as of Mar 1, 2019
Niall Murphy	Jan 14, 2019	No balance on record
Thomas O'Neil	Aug 17, 2018	30,560 shares, last reported balance as of Aug 15, 2018
Armen Shanafelt	Jun 12, 2018	2,099,482 shares, last reported balance as of Aug 16, 2016
CANAAN X L.P.	May 21, 2018	2,116,552 shares, last reported balance as of May 17, 2018
ADAGE CAPITAL PARTNERS GP, L.L.C.	Jun 1, 2017	2,056,076 shares, last reported balance as of May 30, 2017
Julie Papanek	May 26, 2017	No balance on record
Julie Papanek	May 26, 2017	2,453,255 shares, last reported balance as of Aug 16, 2016
William Hodder	Oct 13, 2016	7,943 shares, last reported balance as of Aug 10, 2016
Johnson Johnson	Aug 18, 2016	2,449,183 shares, last reported balance as of Aug 16, 2016
LV Management Group, LLC	Aug 16, 2016	2,099,482 shares, last reported balance as of Aug 16, 2016

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Protagonist Therapeutics, Inc insiders sold $87.7M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the Protagonist Therapeutics, Inc CEO selling stock?

Why are Protagonist Therapeutics, Inc insiders selling?

Are any Protagonist Therapeutics, Inc insiders buying?

The evidence

No plan disclosed · $31.1M

Taxes

Charitable gifts · 6K shares

Sales by month